Skip to main content
OpenTrials
Completed

NCT Number: NCT04788563

A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

Heat-sensitive moxibustion, an important mean of external therapy of traditional Chinese medicine, has unique advantages in treating various chronic diseases than common moxibustion. This study aims to evaluate the efficacy, safety, and cost-effectiveness of heat-sensitive moxibustion for primary hypertension under community self-management setting using a multicenter, pragmatic, randomized controlled trial design with patient-preference arms.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Erliuling, Nanchang, Jiangxi, China

Loading trial locations.

About this study

Primary hypertension is a common chronic disease that threatens the life and health of human beings. The conventional western drug therapy often has side effects and many patients are unable to achieve ideal blood pressure control with drugs alone. Therefore, the treatment of primary hypertension still requires active exploration of complementary and alternative therapies with clear clinical efficacy.

Heat-sensitive moxibustion is an innovative moxibustion therapy. By stimulating the patient's special moxibustion sensation, heat-sensitive moxibustion can achieve better results than traditional moxibustion for many diseases, including primary hypertension. Heat-sensitive moxibustion is an easy, inexpensive and safe treatment method. The practitioner does not need to be professionally qualified to perform moxibustion, making it a suitable technique for patients to self-medicate on a daily basis. Traditional moxibustion has been shown to lower blood pressure in patients with primary hypertension. Theoretically, heat-sensitive moxibustion could achieve better blood pressure lowering effects, but its effects in lowering blood pressure in the setting of self-management in community patients is unclear. To verify the efficacy and safety of heat-sensitive moxibustion community self-management for hypertension, we plan to perform a randomized controlled trial. In this trial, we designed the trial grouping scheme as a randomized controlled trial with patient preference arms in order to improve patient adherence and reduce the impact of patient preference effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with essential hypertension, i.e., systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg, with a course more than 6 months.
  • Ages: 18-80 years;
  • The original antihypertensive drugs are calcium channel blockers and/or angiotensin II receptor blockers.
  • Did not receive acupoint stimulation therapies for hypertension in the last month.
  • Patients in the heat-sensitive moxibustion groups need to develop at least one type of moxibustion sensation around the following acupoints: Yongquan, Baihui, Shenque, Quchi, Zusanli, Hegu, Taichong and Dazhui.
  • Consent to sign an informed consent form

Exclusion criteria

  • Systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg after taking antihypertensive drugs;
  • Secondary hypertension.
  • Pregnancy and lactation;
  • Allergic to moxibustion devices, moxa smoke or Artemisia argyi.
  • Complicated with severe diseases that are not recommended for heat-sensitive moxibustion, such as acute cerebral hemorrhage, hypertensive crisis, sensory disturbances, serious mental diseases, etc.

Treatment and study plan

Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)

Other

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Original antihypertensive treatment (compulsively randomized arm)

Drug

In this group, patients will maintain their original antihypertensive treatment.

Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)

Other

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Original antihypertensive treatment (voluntarily randomized arm)

Drug

In this group, patients will maintain their original antihypertensive treatment.

Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)

Other

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Original antihypertensive treatment (preference selection arm)

Drug

In this group, patients will maintain their original antihypertensive treatment.

Primary outcomes

  1. Systolic blood pressure

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Changes from baseline in systolic blood pressure

Secondary outcomes

  1. Diastolic blood pressure

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Changes from baseline in diastolic blood pressure

  2. Response to treatment

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Definition: (i) a decrease in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg; or (ii) blood pressure control of < 140 mmHg systolic and < 90 mmHg diastolic in patients aged ≥ 65 years; blood pressure control of < 130 mmHg systolic and < 80 mmHg diastolic in patients aged < 65 years.

  3. Dose of antihypertensive drugs

    Time frame: Measure at baseline screening, monthly for 6 months

    Changes from baseline in dose of antihypertensive drugs

  4. Score of EQ-5D-5L

    Time frame: Baseline and months 3 and 6

    Quality of life will be measured using Euro-Qol-5 Dimensions-5 Levels questionnaire (EQ-5D-5L)

  5. Symptom score

    Time frame: Baseline and months 3 and 6

    Symptoms will be scored using the scale in "Guiding Principles of Clinical Research on New Drugs of Chinese Medicines"

  6. Cost-effectiveness ratio

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Outpatient and inpatient costs for each group will be recorded and used to calculate the cost-effectiveness ratio

  7. Patients' compliance to heat-sensitive moxibustion

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Patients' compliance will be assessed by recording the frequency and duration of heat-sensitive moxibustion.

  8. Incidence of cardiovascular events

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Newly developed cardiovascular events

  9. Any adverse events

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Adverse event data will be derived from patient self-reports and physician reviews.

  10. Heat-sensitive moxibustion-related adverse events

    Time frame: Baseline and months 1, 2, 3, 4, 5, and 6

    Heat-sensitive moxibustion-related adverse event data will be derived from patient self-reports and physician reviews.

Sponsors and collaborators

Lead sponsor

Jiangxi University of Traditional Chinese Medicine

Other

Registry information

Official study title

Heat-sensitive Moxibustion Self-administration for Primary Hypertension in Community: A Multicenter, Pragmatic, Randomized Controlled Trial With Patient Preference Arms

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 9, 2021
Registry last updated
Jul 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.